TCI Wealth Advisors Inc. Has $516,000 Holdings in Danaher Corporation (NYSE:DHR)

TCI Wealth Advisors Inc. trimmed its position in Danaher Corporation (NYSE:DHR - Free Report) by 67.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,515 shares of the conglomerate's stock after selling 5,170 shares during the quarter. TCI Wealth Advisors Inc.'s holdings in Danaher were worth $516,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in DHR. Fortis Capital Advisors LLC grew its position in Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after purchasing an additional 50 shares in the last quarter. Fayez Sarofim & Co grew its holdings in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after buying an additional 50 shares in the last quarter. Perennial Investment Advisors LLC raised its position in Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after buying an additional 51 shares during the period. Finally, Sound View Wealth Advisors Group LLC lifted its stake in Danaher by 3.1% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after acquiring an additional 52 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Stock Performance

DHR opened at $194.36 on Thursday. The stock has a 50-day moving average of $193.46 and a 200-day moving average of $210.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a market cap of $139.10 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 2.75 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.66%. Danaher's payout ratio is presently 24.85%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. Wall Street Zen downgraded Danaher from a "buy" rating to a "hold" rating in a report on Monday, June 9th. Wolfe Research dropped their price objective on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research note on Monday, April 7th. Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price for the company in a research report on Friday, March 14th. Robert W. Baird lowered their price target on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, Evercore ISI dropped their price target on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 22nd. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $248.17.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.